CDK2 and prostate cancer: As a star molecule, CDK2 (Kawakami et al., 2020) participates in classic pathways in various cancers, such as colorectal cancer (Somarelli et al., 2020), neuroblastoma (Poon et al., 2020), breast cancer (Hur et al., 2020), hepatocellular carcinoma (Hou et al., 2019), and prostate cancer (Washino et al., 2019).